Bessemer Group’s Editas Medicine EDIT Stock Holding History

Bessemer Group’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-43,636	Closed	-$732K	–	1807
2017 Q2	$732K	Buy	+43,636	New	+$786K	﹤0.01%	757
2017 Q1	–	Sell	-21,818	Closed	-$354K	–	1786
2016 Q4	$354K	Hold	21,818	–	–	﹤0.01%	969
2016 Q3	$294K	Buy	+21,818	New	+$447K	﹤0.01%	902

Other funds holding EDIT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PVMCV

Polaris Venture Management Co VI Boston, Massachusetts $43.1M AUM 78.12% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bessemer Group's EDIT Position: Q3 2017 in Review

Bessemer Group sold out of Editas Medicine (EDIT) in Q3 2017, closing a stake of 43,636 shares — an estimated $732K sold.

Bessemer Group first reported a position in EDIT in Q3 2016 and held it in 3 quarters. The position peaked at $732K in Q2 2017. 116 funds tracked by Wall St. Rank hold EDIT as of Q3 2017.

Bessemer Group reported no remaining Editas Medicine position as of Q3 2017 after selling out during the quarter.
Bessemer Group sold 43,636 Editas Medicine shares in Q3 2017, an estimated $732K.
Bessemer Group first reported a position in Editas Medicine in Q3 2016 and held it in 3 quarters.
Bessemer Group's Editas Medicine position peaked at $732K in Q2 2017.
116 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2017.

Based on Bessemer Group's 13F filing for Q3 2017, filed 3 Nov 2017.